The Lactobacillus gasseri G098 Strain Mitigates Symptoms of DSS-Induced Inflammatory Bowel Disease in Mice.
The Lactobacillus gasseri G098 Strain Mitigates Symptoms of DSS-Induced Inflammatory Bowel Disease in Mice.
复制标题
DOI：
10.3390/nu14183745
复制
发表时间：
2022-09-10
期刊：
影响因子：
5.9
通讯作者：
Chen YF
中科院分区：
文献类型：
--
作者：
Zhang WQ;Quan KY;Feng CJ;Zhang T;He QW;Kwok LY;Chen YF
炎症性肠病（IBD）是一种反复发作的胃肠道炎症性疾病，病因不明，但被认为与免疫异常、肠道微生物失调等因素有关。益生菌可以调节宿主免疫和肠道菌群；因此，我们研究了气态乳杆菌G098 （G098）对右旋糖酐硫酸钠（DSS）诱导小鼠结肠炎的缓解作用及其机制。将小鼠分为正常对照组（NC）、DSS诱导结肠炎小鼠（DSS）和结肠炎小鼠（G098）三组，每组8只。我们的研究结果显示，给予G098有效地逆转了DSS引起的结肠炎相关症状（减轻体重减轻，降低疾病活动指数和病理评分；所有病例p < 0.05），并预防了DSS引起的死亡率（DSS组62.5%，G098组100%）。与DSS组相比，G098组的死亡率和症状改善伴随着更健康的血清细胞因子平衡(血清促炎因子、白细胞介素（IL)-6 [p < 0.05]、IL-1β [p < 0.01]、肿瘤坏死因子(TNF)-α [p < 0.001]、血清抗炎因子IL-13 [p < 0.01]）和肠道微生物群调节（以更高的肠道微生物群多样性为特征[p < 0.05]）。与dss处理组相比，厚壁菌门（Firmicutes）和Lachnoclostridium显著增加[p < 0.05]，拟杆菌门（Bacteroidetes）显著减少[p < 0.05]，糖降解相关途径基因丰度显著提高[p < 0.05]。综上所述，我们的研究结果表明，摄入G098可以通过调节宿主免疫和肠道微生物组来减轻dss诱导的结肠炎，菌株治疗是治疗IBD的一种很有前途的策略。
Inflammatory bowel disease (IBD) is a recurring inflammatory disease of the gastrointestinal tract with unclear etiology, but it is thought to be related to factors like immune abnormalities and gut microbial dysbiosis. Probiotics can regulate host immunity and gut microbiota; thus, we investigated the alleviation effect and mechanism of the strain Lactobacillus gasseri G098 (G098) on dextran sodium sulfate (DSS)-induced colitis in mice. Three groups of mice (n = 8 per group) were included: normal control (NC), DSS-induced colitis mice (DSS), and colitis mice given strain (G098). Our results showed that administering G098 effectively reversed DSS-induced colitis-associated symptoms (mitigating weight loss, reducing disease activity index and pathology scores; p < 0.05 in all cases) and prevented DSS-induced mortality (62.5% in DSS group; 100% in G098 group). The mortality rate and symptom improvement by G098 administration was accompanied by a healthier serum cytokine balance (significant decreases in serum pro-inflammatory factors, interleukin (IL)-6 [p < 0.05], IL-1β [p < 0.01], and tumor necrosis factor (TNF)-α [p < 0.001], and significant increase in the serum anti-inflammatory factor IL-13 [p < 0.01], compared with DSS group) and gut microbiome modulation (characterized by a higher gut microbiota diversity [p < 0.05], significantly more Firmicutes and Lachnoclostridium [p < 0.05], significantly fewer Bacteroidetes [p < 0.05], and significant higher gene abundances of sugar degradation-related pathways [p < 0.05], compared with DSS-treated group). Taken altogether, our results suggested that G098 intake could mitigate DSS-induced colitis through modulating host immunity and gut microbiome, and strain treatment is a promising strategy for managing IBD.
登录
查看更多内容
DOI：
10.1038/s41575-020-00360-x
发表时间：
2021-01
期刊：
Nature reviews. Gastroenterology & hepatology
影响因子：
--
作者：
Kaplan GG;Windsor JW
通讯作者：
Windsor JW
影响因子：
4.6
作者：
Kang L;Li P;Wang D;Wang T;Hao D;Qu X
通讯作者：
Qu X
影响因子：
29.4
作者：
Lee M;Chang EB
通讯作者：
Chang EB
影响因子：
12.2
作者：
Jang, You Jin;Kim, Woon-Ki;Ko, Gwangpyo
通讯作者：
Ko, Gwangpyo
影响因子：
2.3
作者：
Hawkey, C. J.
通讯作者：
Hawkey, C. J.